Khan Abbas, Saleem Shoaib, Idrees Muhammad, Ali Syed Shujait, Junaid Muhammad, Chandra Kaushik Aman, Wei Dong-Qing
State Key Laboratory of Microbial Metabolism and College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China; Center for Biotechnology and Microbiology, University of Swat, Pakistan.
Center for Biotechnology and Microbiology, University of Swat, Pakistan.
J Mol Graph Model. 2018 Jun;82:37-47. doi: 10.1016/j.jmgm.2018.03.004. Epub 2018 Apr 11.
Dengue virus belongs to a group of human pathogens, which causes different diseases, dengue hemorrhagic fever and dengue shock syndrome in humans. It possesses RNA as a genetic material and is replicated with the aid of NS5 protein. RNA-dependent RNA polymerase (RdRp) is an important domain of NS5 in the replication of that virus. The catalytic process activity of RdRp is making it an important target for antiviral chemical therapy. To date, No FDA drug has been approved and marketed for the treatment of diseases caused by Dengue virus. So, there is a dire need to advance an area of active antiviral inhibitors that is safe, less expensive and widely available. An experimentally validated complex of Dengue NS5 and compound 27 (6LS) were used as pharmacophoric input and hits were identified. We also used Molecular dynamics (MD) simulations alongside free energy and dynamics of the internal residues of the apo and holo systems to understand the binding mechanism. Our analysis resulted that the three inhibitors (ZINC72070002, ZINC6551486, and ZINC39588257) greatly affected the interior dynamics and residual signaling to dysfunction the replicative role of NS5. The interaction of these inhibitors caused the loss of the correlated motion of NS5 near to the N terminus and helped the stability of the binding complex. This investigation provided a methodological route to discover allosteric inhibitors against the epidemics of this Flaviviruses. Allosteric inhibitors are important and major assets in considering the development of the competitive and robust antiviral agents such as against Dengue viral infection.
登革热病毒属于一组人类病原体,可导致不同疾病,如人类的登革出血热和登革休克综合征。它以RNA作为遗传物质,并在NS5蛋白的帮助下进行复制。RNA依赖性RNA聚合酶(RdRp)是该病毒复制过程中NS5的一个重要结构域。RdRp的催化过程活性使其成为抗病毒化学疗法的一个重要靶点。迄今为止,尚无FDA批准的药物用于治疗由登革热病毒引起的疾病。因此,迫切需要开发一种安全、廉价且广泛可用的活性抗病毒抑制剂领域。以登革热NS5与化合物27(6LS)的实验验证复合物作为药效团输入并鉴定出命中物。我们还使用分子动力学(MD)模拟以及无配体和全酶系统内部残基的自由能和动力学来理解结合机制。我们的分析结果表明,三种抑制剂(ZINC72070002、ZINC6551486和ZINC39588257)极大地影响了内部动力学和残余信号,使NS5的复制作用功能失调。这些抑制剂的相互作用导致NS5靠近N端的相关运动丧失,并有助于结合复合物的稳定性。这项研究提供了一条方法路线,以发现针对这种黄病毒流行的变构抑制剂。在考虑开发竞争性和强大的抗病毒药物(如针对登革热病毒感染的药物)时,变构抑制剂是重要且主要的资产。